Archives: Speakers

After spending more than 20 years in the public switching industry, Ingo Kraft founded KraftCom in 1999. His goal is to stay at the cutting-edge of hotel guest infotainment solutions, which led KraftCom to become one of the leading system suppliers for in-house networks and digital guest-facing applications. He studied computer science with emphasis on software architecture.

Tankut Turhan is founder & CEO at Nevotek. He holds a bachelor’s degree in Electrical Engineering. He worked reputable global technology companies throughout his career. Under his entrepreneur leadership and with his extensive international experience in Unified Communications Systems, Nevotek evolved to be a global company serving Hospitality, Healthcare, Marine sectors.

Focused on the development and execution of Flint Group Packaging Inks’ Vision, Strategy & Marketing, Thomas works cross-functionally with stakeholders across our global operations. Having previously worked for a packaging converter, Thomas’ understands the opportunities and challenges of our time, across the industry.

Benjamin Köhler is Chief Sales Officer and Co-Founder of Betterspace, one of the leading 360 software providers of digital solutions for the hotel industry, the software company he co-founded has more than 800 customers in over 10 countries. With a lot of enthusiasm, the committed entrepreneur continues to push the internationalization of the tec supplier.

Dr. Mishra (Ex-Genentech, Ex-NCI, Ex-NIH) is the Founder and CEO of Agility Pharmaceuticals. He is a serial entrepreneur who founded his first company after graduating high school, and second company during his PhD. Since then, he has accumulated a wealth of experienced by building, investing and advising numerous other companies. He is an investor/ co-founder/ board member of a few US based corporations focused on accelerating drug discovery & development, blockchain & digital health. Dr. Mishra is also founding president & CEO of American Association for Precision Medicine (AAPM) and is leading research efforts focused on preventing & curing chronic diseases; not only treating the sick but also providing knowledge/tools to individuals to live longer, healthier lives.

Widely recognized as a thought leader in the field of Technology and Healthcare, Dr. Mishra has keynoted, chaired, curated and organized numerous successful international conferences. Prior to Agility Pharma, Dr. Mishra served as a scientist and Principal Investigator at Genentech, Roche. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics and several drugs/ combinations in the clinic.

His research work has been recognized globally by over 40 prestigious awards and honors. Due to his unique perspective & selfless service, he is highly respected & sought-after mentor to many. The companies that he has advised have raised multimillion dollars. Notably, he serves as a mentor and advisor to startup accelerators such as IndieBio, Health2.0’s Project Zygote and CLSI FAST program, to help grow California’s life sciences innovation ecosystem.

Near 20 years profound global leadership in Oncology Clinical Research, Regulatory Filing, Product Launch, and Business Development at the prestigious pharmaceutical companies such as Merck, Novartis, Pfizer, innovative biotech Exelixis, well-established Asian pharmaceutical company Sihuan, and cell therapy start-up CARsgen. Holding in-depth knowledge and practical leadership skills to strategically manage cross functions and efficiently deliver the results and bet the company objectives in widespread areas, including but not limited to, Pharmaceutical Quality/CMC, Nonclinical Pharmacology and Toxicology, Global Clinical Development (early to late phase, innovative & generic), Global Regulatory Submission (NDA/BLA/aNDA), Global Commercial and Product Launch, Global Business Development (Licensing In/Out, Mergers and Acquisitions), and Asset Life Cycle Management.

Leading and being major contributor for multiple oncology global regulatory submissions, including one BLA, one NDA, two MAAs, and three INDs. Proactively planned and attended numerous TC/F2F meetings (i.e. post-IND, End of Phase 2, pre-BLA, pre-MAA, post-BLA orientation, etc) with FDA, EMA, and managed numerous response and interactions to address the inquiries from ROW regulatory agencies (i.e. SWISS MEDIC, Health Canada, Australia TGA, Japan PMDA/MHLW, China FDA, etc)

Clinical Operations Leader with extensive industry and clinical trial management experience with ability to manage high-performance teams and develop cost effective solutions.

Experience covers a multitude of aspects of clinical programs in Phase I, II, III, IIIB, and IV, globally.

Ethical and sequential problem solver with multi-therapeutic acumen in clinical study management;
and a proven track record of establishing, strengthening, and improving the processes and infrastructures through interfacing with various arms of organizations including Regulatory Affairs, CMC, Project Management Teams, and other KOLs and clinical team members.

Experienced Supply Chain professional and Certified Lean Greenbelt Champion with a demonstrated history of working in the pharmaceutical/biotechnology industry. Skilled in Supply Chain Strategy, Operations Management, Cross-Functional Leadership, and Continuous Improvement.

A result-oriented technical leader with extensive drug product (solid oral, oral liquid, parenteral) development experience ranging from Discovery Support through clinical development.

• Direct experience in managing multiple CDMOs to plan, coordinate, and execute external drug product development and manufacturing activities.
• Proven record of excellence at project management, workflow development, innovative technology implementation, and timeline/budget management.
• Technical expertise: pre-formulation, formulation and process development, biopharmaceutics, and PBPK modeling.
• Broad knowledge in drug development and direct experience in managing CMC team functions within multi-disciplinary (Discovery, CMC, Drug Safety, DMPK, Clinical Operations) development team.
• Highly collaborative, change-agile, and strong problem-solving ability in a fast-paced matrix environment.